We talk to the experts about the increasing use of telemedicine in rheumatology during the COVID-19 pandemic, exploring what needs to be considered for different rheumatic diseases and whether telerheumatology is here to stay.
John Stone talks about the BACC Bay Tocilizumab Trial, which demonstrated similar outcomes among hospitalized COVID-19 patients treated with the IL-6 inhibitor versus placebo in addition to standard care (6:47).
Spotlight on: Repurposing rheumatology drugs for COVID-19
Findings from three randomized controlled trials suggest that treatment with the IL-6 inhibitor tocilizumab has little benefit for hospitalized patients with COVID-19.
Guidance for rheumatologists
Guidance and expert opinion on rheumatology practice during the COVID-19 pandemic
